The decision to stop the study is based on the recommendation by the Independent Data Monitoring Committee (IDMC). IDMC monitoring showed an inferior efficacy of asundexian compared to the control arm of the study.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Ish6WZx
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» Bayer cancels asundexian phase III study program
https://ift.tt/uXzbnZJ
No comments:
Post a Comment